Needham & Company LLC restated their buy rating on shares of Crispr Therapeutics (NASDAQ:CRSP) in a research note released on Monday, December 23rd, AnalystRatings.com reports. Needham & Company LLC currently has a $84.00 price target on the stock.
A number of other equities analysts have also commented on CRSP. Wells Fargo & Co reissued a buy rating on shares of Crispr Therapeutics in a research note on Friday, December 6th. BidaskClub downgraded Crispr Therapeutics from a strong-buy rating to a buy rating in a research report on Friday, December 13th. William Blair upgraded Crispr Therapeutics from a market perform rating to an outperform rating in a research report on Tuesday, November 19th. Oppenheimer boosted their target price on Crispr Therapeutics from $65.00 to $80.00 and gave the stock an outperform rating in a research report on Monday, November 25th. Finally, Roth Capital boosted their target price on Crispr Therapeutics from $65.00 to $100.00 in a research report on Tuesday, November 19th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and fourteen have issued a buy rating to the company. The company has a consensus rating of Buy and a consensus target price of $71.38.
CRSP opened at $66.01 on Monday. The business has a 50-day moving average of $64.60 and a 200-day moving average of $50.48. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32. Crispr Therapeutics has a fifty-two week low of $26.00 and a fifty-two week high of $74.00. The company has a market capitalization of $3.64 billion, a PE ratio of -19.19 and a beta of 3.30.
Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The company had revenue of $211.93 million for the quarter, compared to the consensus estimate of $6.32 million. On average, equities research analysts expect that Crispr Therapeutics will post 0.65 earnings per share for the current fiscal year.
In other news, President Rodger Novak sold 33,618 shares of the company’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the transaction, the president now directly owns 33,618 shares of the company’s stock, valued at $2,353,260. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total value of $412,500.00. Following the transaction, the director now directly owns 7,500 shares of the company’s stock, valued at $412,500. The disclosure for this sale can be found here. Insiders have sold 56,118 shares of company stock valued at $3,620,760 over the last ninety days. 21.40% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Nikko Asset Management Americas Inc. increased its stake in shares of Crispr Therapeutics by 48.4% during the third quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock worth $113,846,000 after purchasing an additional 906,006 shares during the period. Orbimed Advisors LLC bought a new position in Crispr Therapeutics during the 3rd quarter worth $21,167,000. Price T Rowe Associates Inc. MD increased its stake in Crispr Therapeutics by 19.6% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock worth $34,801,000 after acquiring an additional 121,176 shares during the period. Wells Fargo & Company MN increased its stake in Crispr Therapeutics by 23.9% during the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock worth $28,443,000 after acquiring an additional 116,540 shares during the period. Finally, Balyasny Asset Management LLC bought a new position in Crispr Therapeutics during the 2nd quarter worth $5,165,000. 49.82% of the stock is owned by hedge funds and other institutional investors.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Story: What is a capital gain?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.